NASDAQ:CRBP

Corbus Pharmaceuticals Q3 2025 Earnings Results & Report

Corbus Pharmaceuticals logo
$2.06 -0.37 (-15.23%)
Closing price 04:00 PM Eastern
Extended Trading
$2.05 -0.01 (-0.49%)
As of 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corbus Pharmaceuticals missed analyst earnings expectations in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$1.90 versus the -$1.80 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
8:00 AM ET

Corbus Pharmaceuticals EPS Results

Actual EPS
-$1.90
Consensus EPS
-$1.80
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Corbus Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.11 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Corbus Pharmaceuticals Q3 2025 Earnings FAQ

Corbus Pharmaceuticals (NASDAQ:CRBP) reported earnings of -$1.90 per share for Q3 2025, missing the consensus estimate of -$1.80. The report was announced on Wednesday, November 12, 2025.

Corbus Pharmaceuticals Earnings Headlines

ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
Corbus Pharmaceuticals Reports Positive Oral Obesity Drug Data
See More Corbus Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Corbus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corbus Pharmaceuticals and other key companies, straight to your email.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals (NASDAQ:CRBP) is a clinical-stage biotechnology company based in Norwood, Massachusetts. It develops investigational medicines, with current research focused on cancer and obesity.

Its oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, and CRB-601, an antibody targeting the αvβ8 integrin. The company is also developing CRB-913, an investigational drug candidate designed to act on the cannabinoid CB1 receptor for obesity treatment. These candidates are in development and are not approved medicines.

Founded in 2014, Corbus previously focused on inflammatory and fibrotic diseases before shifting its research toward oncology and metabolic disorders. The company is led by co-founder and Chief Executive Officer Yuval Cohen.

View Corbus Pharmaceuticals Profile